There aren't many biotechs that are more exciting than Viking Therapeutics (VKTX -7.45%) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could see its shares soar for years. But that doesn't mean you should rush to buy the stock without understanding what else is going on with this stock and why it's making the changes it's making. Let's examine three things you'll need to factor into your decision if you plan on investing in Viking Therapeutics ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (VKTX -7.45%), a mid-cap biotech that rose in prominence this year. The drugmaker's shares are up by nearly 200% since January.However, while many investors are excited about Viking's prospects, others worry they have already missed the boat. How much upside does a clinical-stage biotech with a market cap of $6.3 billion have? Is it too late to invest in Viking Therapeutics, or do the company's shares rem ...

Mergers and acquisitions could make a comeback with Trump headed back to Washington.The 2024 presidential election and President-elect Donald Trump is headed back to Washington. The Republican party also won control of the Senate and the House of Representatives.If Trump's previous tenure in the Oval Office is an indicator for what can be expected, there's a good chance for a less stringent regulatory environment.One of my big predictions under a Trump presidency is that mergers and acquisitions (M&A) will ...

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.So far this year, Eli Lilly (LLY 0.54%) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth of its diabetes and obesity care treatments, Lilly has also secured some major wins from the Food and Drug Administration (FDA), including approval for both its Alzheimer's disease candidate and eczema drug.While it looks ...

Results to be Featured in Oral Late Breaker PresentationSAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also ...

Viking stock has slipped more than 20% from its peak.Viking Therapeutics (VKTX -0.54%) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big pharma companies Eli Lilly and Novo Nordisk. And in just one trading session, the shares skyrocketed, rising more than 100%.Since then, Viking has reitera ...

All signs are pointing toward its continued success.When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the stock will go up." And while that proposition is certainly true with Viking Therapeutics, (VKTX 4.52%) there's more than one reason for why the stock is worth buying.In fact, there are at least four arguments supporting an investment, so let's take a look at each.1. It's racing closer to generating revenue for the first timeViking i ...

The company's latest presentation supports the idea that its lead program will make billions.With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (VKTX 1.44%) are a hot commodity, to say the least. And as of early November, there's one more big green flag suggesting that investors who take the plunge will be wealthier than before. Even an investment on the scale of $5,000 could see a meaningful run-up, assuming its plans to compete in the market for anti-obesity medicines com ...

文章核心观点 - 公司正在开发一种可能创造销售记录的抗肥胖药物 [1] - 公司之前的实验结果已经引起了整个股票市场的关注,公司股价在2024年上涨了256% [2] - 公司的实验性药物VK2735可能成为下一代最佳双GLP-1/GIP激动剂 [5] 根据相关目录分别进行总结 公司概况 - 公司是一家处于临床阶段的制药公司,专注于开发抗肥胖药物 [1] - 公司股价在2024年上涨了256% [2] 行业概况 - 对于有效的体重管理治疗方法存在巨大需求 [3] - 赛美格鲁肽(Ozempic和Rybelsus)和泰尔津帕肽(Mounjaro)等GLP-1类药物销售额快速增长 [4][5] - GLP-1类药物销售额预计将从2024年的近500亿美元增长到2029年的超过1000亿美元 [9] 公司产品情况 - 公司的实验性药物VK2735是一种双GLP-1/GIP激动剂,可能成为下一代最佳选择 [5] - VK2735注射剂在临床试验中显示出良好的疗效,患者平均减重14.7% [5][6] - VK2735口服制剂在临床试验中也显示出良好的疗效,患者平均减重6.8% [7][8] 公司发展前景 - VK2735注射剂还需要完成为期一年以上的3期临床试验,预计最早2025年才能上市 [9][10] - 公司目前市值75亿美元,对于一家尚未有收入的临床阶段公司来说估值较高 [10][11] - 如果VK2735成为市场领导者,公司股价还有较大上涨空间 [11] - 但在VK2735上市前还存在诸多不确定性,投资该股票风险较高 [12]

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?For high-profile biotech Viking Therapeutics (VKTX -13.36%), Monday was very much a good news/bad news kind of day. The company reported quite encouraging clinical results from a version of its investigational weight-loss drug. Before long, however, this was overshadowed by promising news from rival developers of similar treatments.Ultimately, after an early surge, Viking's shares closed the day more than 13% lower in price.Weight loss for profi ...